Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials

Mark F. Lew, John T. Slevin, Rejko Krüger, Juan Carlos Martínez Castrillo, Krai Chatamra, Jordan S. Dubow, Weining Z. Robieson, Janet A. Benesh, Victor S.C. Fung

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Background: Levodopa-carbidopa intestinal gel (LCIG) provides continuous infusion and reduces "off" time in advanced Parkinson's disease (PD) patients with motor fluctuations despite optimized pharmacotherapy. Methods: Clinical experience with 2 LCIG dosing paradigms from phase 3 studies was examined. In an open-label, 54-week study, LCIG was initiated as daytime monotherapy via nasojejunal (NJ) tube then switched to percutaneous endoscopic gastrojejunostomy (PEG-J) tube; adjunctive therapy was permitted 28 days postPEG-J. In a 12-week, double-blind, placebo-controlled, double-dummy trial, patients continued stable doses of existing anti-PD medications, but LCIG replaced daytime oral levodopa-carbidopa and was initiated directly via PEG-J. Results: In the open-label study, 92% of 354 patients received monotherapy at post-PEG-J week 4; mean titration duration was 7.6 days; dosing remained stable post-titration (mean total daily dose [TDD] was 1572mg at last visit). In the double-blind trial, 84% received polypharmacy; mean titration took 7.1 days for the LCIG arm (TDD post-titration: 1181mg; n=37). At post-PEG-J week 4, mean "off" time with LCIG was reduced by 3.9h (open-label/monotherapy study) and 3.7h (double-blind/polypharmacy trial). NJ treatment (open-label study only) required an additional procedure with related adverse events (AEs) and withdrawals. The most common AEs during PEG-J weeks 1-4 in the open-label/monotherapy and double-blind/polypharmacy trials, respectively, were complication of device insertion (35%, 57%) and abdominal pain (26%, 51%). Discontinuations due to nonprocedure/nondevice AEs were low (2.2%, 2.7%). Conclusion: These results support the option of initiating LCIG with or without NJ and as either monotherapy or polypharmacy.

Original languageEnglish
Pages (from-to)742-748
Number of pages7
JournalParkinsonism and Related Disorders
Issue number7
StatePublished - Jul 1 2015

Bibliographical note

Funding Information:
AbbVie Inc. funded the studies ( NCT00335153 , NCT00660387 , and NCT00357994 ). AbbVie Inc. participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. Funding for editorial support was provided by AbbVie Inc. to The Curry Rockefeller Group, LLC; medical writing assistance was provided by Susan Kralian, PhD, and John Norwood of The Curry Rockefeller Group, LLC.

Publisher Copyright:
© 2015 AbbVie Inc, employer of authors K. Chatamra,W. Robieson, and J. Benesh.


  • Dosing
  • Levodopa-carbidopa intestinal gel
  • Motor fluctuations
  • PEG-J procedure
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology


Dive into the research topics of 'Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials'. Together they form a unique fingerprint.

Cite this